Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 21, 2003. The report serves as a notification of major interests in the Company's shares received from Barclays in compliance with Part VI of the Companies Act 1985.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding share ownership and does not contain financial performance data.
Material Changes
The filing details a specific shareholding interest held by various Barclays entities as of February 17, 2003. The total holding across 15 registered entities amounts to 180,980,055 shares, representing 3.00% of the Company's issued share capital.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the shareholding notification.
Key Facts for Investor Verification
- Barclays entities collectively hold 180,980,055 shares of GlaxoSmithKline plc.
- This aggregate holding represents exactly 3.00% of the Company's issued share capital.
- The largest single holding within the group is held by Barclays Global Investors Limited (88,449,756 shares).
- The notification was received on February 17, 2003, and reported on February 21, 2003.